Skip to main content
David Abramson, MD, Ophthalmology, New York, NY

DavidAbramsonMD

Ophthalmology New York, NY

Physician

Overview of Dr. Abramson

Dr. David Abramson is an ophthalmologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. Dr. Abramson received Dr. Abramsons medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 48 years. Dr. Abramson is experienced in retinoblastoma, orbital tumors, and intraocular melanoma. He is the first Chief of Ophthalmic Oncology at MSKCC where he is a tenured professor in Surgery, Pediatrics and Radiation oncology. He has published more than 800 articles which have been cited more than 20,000 times.

Education & Training

  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 1969

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1970 - 2026
  • CO State Medical License
    CO State Medical License 2000 - 2025
  • MA State Medical License
    MA State Medical License 1973 - 2019
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Lifetime Achievement Award American Academy of Ophthalmology, 2015
  • Stallard Medal Cambridge University, 2015
  • Heed Alumni Award Heed Foundation, 2012
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Growth Patterns of Survivors of Retinoblastoma Treated with Ophthalmic Artery Chemosurgery  
    Jasmine H Francis, Y Pierre Gobin, David H Abramson, PLoS One
  • Total Retinal Detachments Due to Retinoblastoma: Outcomes Following Intra-Arterial chemotherapy/ophthalmic Artery Chemosurgery  
    Ira J Dunkel, Jasmine H Francis, Y Pierre Gobin, Scott E Brodie, David H Abramson, PLoS One

Press Mentions

  • Hearing Evaluations in Children with Retinoblastoma Treated with Intra-Arterial Carboplatin Chemotherapy: A Single Institution Review
    Hearing Evaluations in Children with Retinoblastoma Treated with Intra-Arterial Carboplatin Chemotherapy: A Single Institution ReviewSeptember 10th, 2024